Navigation Links
Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of specialty generic products.
Date:7/31/2013

LYNDHURST, N.J., July 31, 2013 /PRNewswire/ -- Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of specialty generic products. Under the terms of the agreement, Amerigen will use its formulation expertise to develop a range of complex generic products and will commercialize such products in the United States.  Forest will make undisclosed milestone payments to Amerigen and will receive royalties on US sales of such products.  In addition, Forest will have an option to acquire rights to register and commercialize certain products in Latin America.

John Lowry, Amerigen's President & CEO commented: "This collaboration is a testament to Amerigen's generic formulation and product development capabilities and enables the company to continue its efforts to build a portfolio of differentiated, high value generic pharmaceuticals. It also enables Amerigen to leverage its product development investments into an array of fast growing emerging markets, with the support of a leading international pharmaceutical company."

About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, the Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.


'/>"/>
SOURCE Amerigen Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
2. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
3. Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
5. Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
6. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
7. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
8. Insight Pharmaceuticals Considers Bananacin -- Banana-Flavored Anacin Tablets -- After Worlds Oldest Man Credits Combo As Secret To Long Life
9. Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
10. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results
11. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
Breaking Medicine News(10 mins):